An Ozempic-style medication designed for overweight cats is becoming available for further development and is being promoted as a potential breakthrough treatment for terminal feline illnesses. OKAVA Pharmaceuticals, a pet medication company, announced the successful completion of a clinical trial for its MEOW-1 drug, a feline GLP-1 agonist. The company said the medication could increase quality of life, promote healthy aging, and potentially become the most impactful life-extending therapy for pet cats. thepostmillennial.com